-------------------------------------------

AVI BioPharma, Inc. (NASDAQ: AVII) closed at $1.03 Friday, trading 278,305 shares.

Company News- September 22, 2008: AVI BioPharma to Present at the UBS Global Life Sciences Conference

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced earlier today that Dr. Leslie Hudson, AVI's President and CEO, will present an update on the continuing transition of AVI from an antisense pioneer into a leading discoverer and developer of RNA-based drugs.

To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs using the company's expanded portfolio of proprietary antisense compounds (PMOs). The company's technology applications leverage distinct mechanisms of action in a range of genetic diseases, genetic disorders and the genetic code of disease-causing organisms. The emerging field of directed alternative RNA splicing represents AVI's newest and most exciting application based on the company's core antisense technology. Functional attributes of this approach may include correcting genetic defects (RNA mutations; which AVI believes could produce promising treatments for Duchenne muscular dystrophy), coding for novel soluble receptors (an exciting and novel approach which could have application in the treatment of inflammatory diseases such as rheumatoid arthritis), and the reduction in activity of immune modulators in disease states (currently being applied to IL-10). AVI's RNA-based drug programs also include blocking mRNA translation. In AVI's biodefense program, this application has been successful against the single-stranded RNA viruses Ebola Zaire and Marburg Musoke in non-human primates and may have value against other viral targets such as HCV, Dengue, Junin, influenza and RSV viruses. This application also will be evaluated in the clinic for the treatment of cardiovascular restenosis by our partner Cook Medical. More information about AVI is available at www.avibio.com.

-------------------------------------------

Broadridge Financial Solutions, Inc. (NYSE: BR) closed at $17.41 Friday, trading 2,185,650 shares.

Company News- September 22, 2008: Broadridge Confirms Barclays Bank and Lehman Brothers Are Clients of Its Securities Processing Business

Broadridge Financial Solutions, Inc. (NYSE: BR) confirmed earlier today that both Barclays Bank PLC and Lehman Brothers, Inc. are clients of its Securities Processing business.

Following approval by the U.S. Bankruptcy Court on Saturday, September 20, 2008, of the sale of substantially all of the assets of Lehman Brothers, Inc. to Barclays, Broadridge is in discussions with both parties about their future processing needs.

About Broadridge

Broadridge Financial Solutions, Inc., with over $2.2 billion in revenues in fiscal year 2008 and more than 40 years of experience, is a leading global provider of technology-based outsourcing solutions to the financial services industry. Our systems and services include investor communication, securities processing, and clearing and outsourcing solutions. We offer advanced, integrated systems and services that are dependable, scalable and cost-efficient. Our systems help reduce the need for clients to make significant capital investments in operations infrastructure, thereby allowing them to increase their focus on core business activities. For more information about Broadridge, please visit www.broadridge.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. FastMoneyTalk.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.businessnetwire.us, www.financialbusinessnews.us, www.markettelegraph.com, www.associatesfortune.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage

CONTACT: FastMoneyTalk.com Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.fastmoneytalk.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Following the conference call, a recording of the call will be available for download on the company's website: www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs using the company's expanded portfolio of proprietary antisense compounds (PMOs). The company's technology applications leverage distinct mechanisms of action in a range of genetic diseases, genetic disorders and the genetic code of disease-causing organisms. The emerging field of directed alternative RNA splicing represents AVI's newest and most exciting application based on the company's core antisense technology. Functional attributes of this approach may include correcting genetic defects (RNA mutations; which AVI believes could produce promising treatments for Duchenne muscular dystrophy), coding for novel soluble receptors (an exciting and novel approach which could have application in the treatment of inflammatory diseases such as rheumatoid arthritis), and the reduction in activity of immune modulators in disease states (currently being applied to IL-10). AVI's RNA-based drug programs also include blocking mRNA translation. In AVI's biodefense program, this application has been successful against the single-stranded RNA viruses Ebola Zaire and Marburg Musoke in non-human primates and may have value against other viral targets such as HCV, Dengue, Junin, influenza and RSV viruses. This application also will be evaluated in the clinic for the treatment of cardiovascular restenosis by our partner Cook Medical. More information about AVI is available at www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Michael Hubbard
(Email Contact)
Director of Corporate Communications
(503) 227-0554

SOURCE: AVI BioPharma, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=9DBAAEC2E69503AC

About Citizens Community Bancorp, Inc.

Citizens Community Bancorp, Inc., based in Eau Claire, Wisconsin, is the holding company for Citizens Community Federal, a federal savings association operating 13 full-service banking offices in Wisconsin, Minnesota and Michigan. Please visit us online at www.citizenscommunityfederal.net.

SOURCE: Citizens Community Bancorp, Inc.

Citizens Community Bancorp, Inc.
John Zettler, 715-836-9994 x109
Senior Vice President and Chief Financial Officer

Shares of AVI BioPharma rose 2 cents to $1.17 in early trading Monday. Ryan Vlastelica rv/vj

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

MMMM